학술논문
Association of Pre-Admission Statin Use With Reduced In-Hospital Mortality in COVID-19.
Document Type
Academic Journal
Author
Chacko SR; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; DeJoy R 3rd; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Lo KB; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Albano J; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Peterson E; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Bhargav R; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Gu F; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Salacup G; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Pelayo J; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Azmaiparashvili Z; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA.; Rangaswami J; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA; Sidney Kimmel College of Thomas Jefferson University, Philadelphia, PA, USA.; Patarroyo-Aponte G; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA; Sidney Kimmel College of Thomas Jefferson University, Philadelphia, PA, USA; Division of Pulmonary and Critical Care and Sleep Medicine, Einstein Medical Center Philadelphia, PA, USA.; Benzaquen S; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA; Division of Pulmonary and Critical Care and Sleep Medicine, Einstein Medical Center Philadelphia, PA, USA.; Gupta E; Department of Medicine, Einstein Medical Center Philadelphia, PA, USA; Division of Pulmonary and Critical Care and Sleep Medicine, Einstein Medical Center Philadelphia, PA, USA. Electronic address: enagupta8@gmail.com.
Source
Publisher: Elsevier Country of Publication: United States NLM ID: 0370506 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-2990 (Electronic) Linking ISSN: 00029629 NLM ISO Abbreviation: Am J Med Sci Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Coronavirus disease-19 (COVID-19) infection is associated with an uncontrolled systemic inflammatory response. Statins, given their anti-inflammatory properties, may reduce the associated morbidity and mortality. This study aimed to determine the association between statin use prior to hospitalization and in-hospital mortality in COVID-19 patients.
Methods: In this retrospective study, clinical data were collected from the electronic medical records of patients admitted to the hospital with confirmed COVID-19 infection from March 1, 2020 to April 24, 2020. A multivariate regression analysis was performed to study the association of pre-admission statin use with in-hospital mortality.
Results: Of 255 patients, 116 (45.5%) patients were on statins prior to admission and 139 (54.5%) were not. The statin group had a higher proportion of end stage renal disease (ESRD) (13.8% vs. 2.9%, p = 0.001), diabetes mellitus (63.8% vs. 35.2%, p<0.001), hypertension (87.9% vs. 61.1%, p < 0.001) and coronary artery disease (CAD) (33.6% vs. 5%, p < 0.001). On multivariate analysis, we found a statistically significant decrease in the odds of in-hospital mortality in patients on statins before admission (OR 0.14, 95% CI 0.03- 0.61, p = 0.008). In the subgroup analysis, statins were associated with a decrease in mortality in those with CAD (OR 0.02, 95% CI 0.0003-0.92 p = 0.045) and those without CAD (OR 0.05, 95% CI 0.005-0.43, p = 0.007).
Conclusions: Our study suggests that statins are associated with reduced in-hospital mortality among patients with COVID-19, regardless of CAD status. More comprehensive epidemiological and molecular studies are needed to establish the role of statins in COVID-19.
Competing Interests: Declaration of Competing Interest No conflict of interest for any of the authors.
(Copyright © 2021. Published by Elsevier Inc.)
Methods: In this retrospective study, clinical data were collected from the electronic medical records of patients admitted to the hospital with confirmed COVID-19 infection from March 1, 2020 to April 24, 2020. A multivariate regression analysis was performed to study the association of pre-admission statin use with in-hospital mortality.
Results: Of 255 patients, 116 (45.5%) patients were on statins prior to admission and 139 (54.5%) were not. The statin group had a higher proportion of end stage renal disease (ESRD) (13.8% vs. 2.9%, p = 0.001), diabetes mellitus (63.8% vs. 35.2%, p<0.001), hypertension (87.9% vs. 61.1%, p < 0.001) and coronary artery disease (CAD) (33.6% vs. 5%, p < 0.001). On multivariate analysis, we found a statistically significant decrease in the odds of in-hospital mortality in patients on statins before admission (OR 0.14, 95% CI 0.03- 0.61, p = 0.008). In the subgroup analysis, statins were associated with a decrease in mortality in those with CAD (OR 0.02, 95% CI 0.0003-0.92 p = 0.045) and those without CAD (OR 0.05, 95% CI 0.005-0.43, p = 0.007).
Conclusions: Our study suggests that statins are associated with reduced in-hospital mortality among patients with COVID-19, regardless of CAD status. More comprehensive epidemiological and molecular studies are needed to establish the role of statins in COVID-19.
Competing Interests: Declaration of Competing Interest No conflict of interest for any of the authors.
(Copyright © 2021. Published by Elsevier Inc.)